Acute psychotropic effects of oral cannabis extract with a defined content of δ9-Tetrahydrocannabinol (THC) in healthy volunteers

Pharmacopsychiatry

Volumn 43, Issue 1, 2010, Pages 24-32

  Kaufmann, R M ^a   Kraft, B ^a   Frey, R ^a   Winkler, D ^a   Weiszenbichler, S ^a   Backer C ^a   Kasper, S ^a   Kress, H G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; DIAZEPAM; DRONABINOL;

ADULT; ANALGESIC ACTIVITY; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SEDATION; SINGLE DRUG DOSE; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; CANNABIS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PAIN MEASUREMENT; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOMOTOR PERFORMANCE; PSYCHOTIC DISORDERS; SELF CONCEPT; TETRAHYDROCANNABINOL; TIME FACTORS; YOUNG ADULT;

EID: 76249113713     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1237397     Document Type: Article

References (72)

1. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996 91 1585-1614
2. Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. Acta Psychiatr Scand 1989 79 505-510
3. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001 178 101-106
4. Baigent M, Holme G, Hafner RJ. Self reports of the interaction between substance abuse and schizophrenia. Aust N Zealand J Psychiatry 1995 29 69-74
5. Barnett G, Licko V, Thompson T. Behavioral pharmacokinetics of marijuana. Psychopharmacology 1985 85 51-56
6. Bird KD, Boleyn T, Chesher GB, et al. Intercannabinoid and cannabinoid-ethanol interactions and their effects on human performance. Psychopharmacology 1980 71 181-188
7. Block RI, Erwin WJ, Farinpour R, et al. Sedative, stimulant, and other subjective effects of marijuana: relationships to smoking techniques. Pharmacol Biochem Behav 1998 59 405-412
8. Bond AJ, Lader MH. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974 47 211-218
9. Borland RG, Nicholson AN. Immediate effects on human performance of a 1,5-benzodiazepine (clobazam) compared with the 1,4-benzodiazepines, chlordiazepoxide hydrochloride and diazepam. Br J Clin Pharmacol 1975 2 215-221
10. Campell FA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001 323 13-16
11. Carney MWP, Bacelle L, Robinson B. Psychosis after cannabis abuse. BMJ 1984 288 1047 (Pubitemid 14115261)
12. Chait LD, Pierri J. Effects of smoked marijuana on human performance: a critical review. In: Murphy LL, Bartke A (eds.) Marijuana/Cannabinoids: Neurobiology and Neurophysiology Boca Raton, CRC Press 1992 387-423
13. Chaudry HR, Moss HB, Bashir A, et al. Cannabis psychosis following bhang ingestion. Br J Addiction 1991 86 1075-1081
14. Craft RM. Sex differences in behavioral effects of cannabinoids. Life Sci 2005 77 2471-2478
15. Curran HV. Benzodiazepines, memory and cognitive function. In: Trimble M, Hindmarch I (eds.) Benzodiazepines Hampshire: Wrightson Biomedical Publishers 2000 17-29
16. 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 2002 164 61-70
17. Devane WA, Dysarz FA, Johnson MR, et al. Determination and characteristics of a cannabinoid receptor in rat brain. Mol Pharmacology 1988 34 605-613
18. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992 258 1946-1949
19. DSouza DC, Perry E, MacDougall L, et al. The pychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 2004 1558-1572
20. ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78 2005 539-548
21. Fant RV, Heishman SJ, Bunker EB, et al. Acute and residual effects of marijuana in humans. Pharmacol Biochem Behav 1998 60 777-784
22. Favrat B, Menetrey A, Augsburger M, et al. Two cases of cannabis acute psychosis following the administration of oral cannabis. BMC Psychiatry 2005 5 17-22
23. Frey R, Decker K, Reinfried L, et al. Effect of rest on physicians' performance in an emergency department, objectified by electroencephalographic analyses and psychometric tests. Crit Care Med 2002 30 2322-2329
24. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964 86 1646-1647
25. Gerrard L, Wheeldon NM, McDevitt DG. Effect of combined atenolol and nifedipine administration on psychomotor performance in normal subjects. Eur J Clin Pharmacol 1995 48 229-233
26. Ghodse AH. Cannabis psychosis. Br J Addiction 1986 81 473-478
27. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev 2007 17 347-361
28. Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alc Rev 2003 22 453-460
29. Grünberger J. [Psychodiagnostik des Alkoholkranken. Methodischer Beitrag zur Bestimmung der Organizität in der Psychiatrie. Article in German] Maudrich, Wien, Austria 1977
30. Grünberger J, Linzmayer L, Dietzl M, et al. The effect of biologically-active light on the noo-and thymopsyche and on psychophysiological variables in healthy volunteers. Int J Psychophysiol 1993 15 27-37
31. Hall W, Solowij N. Long-term cannabis use and mental health. Br J Psychiatry 1997 171 107-108
32. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998 352 1611-1616
33. Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust NZ J Psychiatry 2000 34 468-475
34. Heishman SJ, Huestis MA, Henningfield JE, et al. Acute and residual effects of marijuana: profiles of plasma thc levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav 1990 37 561-565
35. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980 10 189-209
36. Holdcroft A, Maze M, Dore C, et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006 104 1040-1046
37. Imade AGT, Ebie JC. A retrospective study of symptom patterns of cannabis-induced psychosis. Acta Psychiatr Scand 1991 83 134-136
38. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001 178 116-122
39. Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag 2001 6 80-91
40. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004 28 849-863
41. Kaufmann RM, Frey R, Battista HJ, et al. Flunitrazepam and driving ability. Fortschr Neurol Psychiatr [Article in German] 2004 72 503-515
42. Kopelowicz A, Vendura J, Libermann RP, et al. Consistency of brief psychiatric rating scale factor structure across a broad spectrum of schizophrenia patients. Psychopathology 2007 41 77-84
43. Kraft B, Frickey NA, Kaufmann RM, et al. Lack Of Analgesia By Oral Standardized Cannabis Extract On Acute Inflammatory Pain And Hyperalgesia In Volunteers. Anesthesiology 2008 109 101-110
44. Kreuz DS, Axelrod J. delta-9-Tetrahydrocannabinol: localization in body fat. Science 1973 179 391-393
45. Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 2001 56 1059-1068
46. Linzmayer L, Arnold O, Saletu-Zylarz GM, et al. Daytime noopsychic and thymopsychic dysfunctions in nonorganic insomnia related to different mental disorders. Somnologie 2002 6 141-148
47. Mason AP, McBay AJ. Cannabis: pharmacology and interpretation of effects. J Forensic Sci 1985 30 615-631
48. Mason OJ, Morgan CJM, Stefanovic A, et al. The psychotomimetic states inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis. Schizophrenia Res 2008 103 138-142
49. Mattila MJ, Vanakoski J, Kalska H, et al. Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol Biochem Behav 1998 59 917-923
50. McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005 10 15A-22A
51. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol 1998 359 1-18
52. Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007 370 319-328
53. Negrete JC. Psychological adverse effects of cannabis smoking: a tentative classification. CMAJ 1973 108 195-202
54. 9- tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacology 2004 24 305-313
55. OLeary DS, Block RI, Koeppel JA, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 2002 26 802-816
56. Overall JE, Gorham DR. The brief psychiatric rating scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmac Bull 1988 24 97-99
57. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997 74 129-180
58. 9-tetrahydrocannabinol. Psychopharmacology 1976 47 141-148
59. Pickworth WB, Rohrer MS, Fant RV. Effects of abused drugs on psychomotor performance. Exp Clin Psychopharmacol 1997 5 235-241
60. Ramaekers J, Kauert G, Theunissen E, et al. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 2009 23 266-277
61. Ranganathan M, DSouza DC. The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology 2006 188 425-466
62. Saletu B, Grünberger J, Cepko H. Pharmaco-EEG and psychometric studies with a novel selective benzodiazepine agonist/antagonist Ro-23-0364. Int J Clin Pharmacol Ther Toxicol 1987 25 421-437
63. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998 59 (Suppl 20) 22-33
64. SPSS Inc. SPSS for Windows Release 15.0. Chicago, IL, USA 19892006
65. Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry 1972 27 133-136
66. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993 163 141-149
67. Tseng AH, Harding JW, Craft RM. Pharmacokinetic factors in sex differences in delta 9-tetrahydrocannabinol-induced behavioral effects in rats. Behav Brain Res 2004 154 77-83
68. Tunving K. Psychiatric effects of cannabis use. Acta Psychiatr Scand 1985 72 209-217
69. Turner JM, de Wit H. Menstrual cycle phase and responses to drugs of abuse. Drug and Alcohol Dependence 2006 84 1-13
70. Vachon L, Sulkowski A, Rich E. Marijuana effects on learning, attention, and time estimation. Psychopharmacologia 1974 39 1-11
71. Webb E, Ashton CH, Kelly P, et al. Alcohol and drug use in UK university students. Lancet 1996 348 922-925
72. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003 362 1517-1526